This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Tumour necrosis factor alpha

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Tumour necrosis factor is a polypeptide cytokine implicated in septic shock. It is produced primarily by mononuclear phagocytes. The stimulus for production includes immune complexes, bacteria and bacterial products including lipopolysaccharide endotoxin.

The effects of TNF are diverse:

  • tumoricidal:
    • increased activation of phospholipases
    • free radical production
    • endonuclease nuclear DNA damage
  • endothelium:
    • increased surface adhesion molecules
    • increased production of platelet activating factor, IL-1 and prostaglandins
    • pro-coagulant effect
  • fibroblasts:
    • increased proliferation
    • increased protease, collagen and collagenase production
  • monocyte, LAK, NK, neutrophil, B- and T-lymphocyte activation
  • systemically:
    • pyrexia
    • increased acute phase proteins
    • decreased appetite
    • increased sleep
    • disordered metabolite handling: negative nitrogen balance, increased glucose release, wasting; hence the alternative term for TNF - cachectin

TNF has been used experimentally against human tumours with poor results due to the frequency of systemic side effects.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.